The city of New Orleans, Louisiana, currently has 100 active clinical trials seeking participants for Cancer research studies.
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
All
Ages:
All
Trial Updated:
03/20/2023
Locations: Louisiana State University Health Sciences Center- New Orleans, New Orleans, Louisiana
Conditions: Breast Cancer
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
Recruiting
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: University Medical Center New Orleans, New Orleans, Louisiana
Conditions: HER2-negative Breast Cancer
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Recruiting
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials. The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2023
Locations: Ochsner Clinic Foundation, New Orleans, Louisiana
Conditions: Cancer, Adult Solid Tumor, Lymphoma, Multiple Myeloma
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Recruiting
The study is a multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2022
Locations: Ochsner Clinic Foundation, New Orleans, Louisiana
Conditions: Locally Advanced Pancreatic Cancer